Melo JV . The molecular biology of chronic myeloid leukaemia Leukemia 1996 10: 751–756 CASPubMed Google Scholar
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Niederwieser D, O'Brien SG, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL . Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study Blood 2002 99: 1928–1937 ArticleCASPubMed Google Scholar
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, O'Brien SG, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ . Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study Blood 2002 99: 3530–3539 ArticleCASPubMed Google Scholar
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037 ArticleCASPubMed Google Scholar
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038–1042 ArticleCASPubMed Google Scholar
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B on behalf of the International STI571 CML Study Group. Imatinib mesylate (Gleevec™) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study N Engl J Med 2002 346: 645–652 ArticleCASPubMed Google Scholar
Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV . Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 2001 98: 3864–3867 ArticleCASPubMed Google Scholar
Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 2000 96: 1070–1079 CASPubMed Google Scholar
Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood 2000 95: 3498–3505 CASPubMed Google Scholar
le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Cambarcorti-Passerini C . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 2000 95: 1758–1766 CASPubMed Google Scholar
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 2000 289: 1938–1942 ArticleCASPubMed Google Scholar
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293: 876–880 ArticleCASPubMed Google Scholar
Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a Article Google Scholar
Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a Article Google Scholar
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP . High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 2002 99: 3472–3475 ArticleCASPubMed Google Scholar
Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002 99: 1860–1862 ArticlePubMed Google Scholar
von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 2002 359: 487–491 ArticleCASPubMed Google Scholar
Cross NCP, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders Leukemia 1994 8: 186–189 CASPubMed Google Scholar
Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T . Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases Leukemia 2002 16: 53–59 ArticleCASPubMed Google Scholar
Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A . Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 1999 13: 1825–1832 ArticleCASPubMed Google Scholar
Cross NCP, Feng L, Bungey J, Goldman JM . Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction Leuk Lymphoma 1993 11 (Suppl. 1): 39–43 Article Google Scholar
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia J Biol Chem 1994 269: 22925–22928 CASPubMed Google Scholar
Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . Identification of CRKL as the constitutively phosphorylated 39- kD tyrosine phosphoprotein in chronic myelogenous leukemia cells Blood 1994 84: 2912–2918 CASPubMed Google Scholar
ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J . Tyrosine phosphorylation of CRKL in Philadelphia + leukemia Blood 1994 84: 1731–1736 CASPubMed Google Scholar
Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ . Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation Blood 1997 89: 297–306 CASPubMed Google Scholar
Senechal K, Heaney C, Druker B, Sawyers CL . Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells Mol Cell Biol 1998 18: 5082–5090 ArticleCASPubMedPubMed Central Google Scholar
Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of STI571 binding to the Abl kinase domain J Biol Chem published 20 June 2002 as 10.1074/jbc.M111525200
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100–104 CASPubMed Google Scholar
Saraste M, Sibbald PR, Wittinghofer A . The P-loop – a common motif in ATP- and GTP-binding proteins Trends Biochem Sci 1990 15: 430–434 ArticlePubMed Google Scholar
Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J, Sawyers CL . Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and _de novo_-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis Blood 2001 98 (Supp. 1): 770a Google Scholar
Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, Superti-Furga G . Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase Oncogene 2001 20: 8075–8084 ArticleCASPubMed Google Scholar
Duesberg P, Stindl R, Hehlmann R . Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortment catalyzed by aneuploidy Proc Natl Acad Sci USA 2001 98: 11283–11288 ArticleCASPubMedPubMed Central Google Scholar
Chase A, Huntly BJP, Cross NCP . Cytogenetics of chronic myeloid leukemia Best Pract Res Clin Haematol 2001 14: 553–571 ArticleCASPubMed Google Scholar
Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG . Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 2002 359: 481–486 ArticleCASPubMed Google Scholar
La Rosée P, O'Dwyer ME, Druker BJ . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective Leukemia 2002 16: 1213–1219 ArticlePubMed Google Scholar